GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc covers the month of October 2022, with a specific reporting date of October 7, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Transaction Price: £13.3049 per share.
- Transaction Volume: Total of 1,512 shares acquired across four individuals.
- Transaction Date: October 6, 2022.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the acquisition of shares by specific executives and their associates.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed as part of a dividend reinvestment plan following dividends paid to shareholders on October 6, 2022.
Key Facts for Investor Verification
- Four individuals (Ms S Jackson, Mr D Jackson, Ms V Whyte, Mr I Whyte, and Ms D Connor) acquired shares via dividend reinvestment.
- All transactions occurred on the same date (October 6, 2022) at the same price (£13.3049).
- The filing is a regulatory disclosure of insider holdings and does not reflect broader company performance.
- Corporate financial results for the period are not included in this specific document.